Nevertheless, as both GLP-1 and FGF21 agonists are being closely studied as therapeutic avenues or NASH, it would be reasonable to consider a combined approach given their distinct mechanisms of action. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.